ESCHERICHIA COLI STRAIN MARKET ANALYSIS

Escherichia Coli Strain Market, By Strain Type (Commensal strains, Diarrheal strains, Extraintestinal pathogenic strains, Uropathogenic strains, Neonatal meningitis strains, and Others), By Application (Diagnostics, Research, Therapeutics, Production of recombinant proteins, Quality control organisms, and Others), By Pathogenicity (Pathogenic E. coli and Non-pathogenic E. coli), By End User (Research Institutes, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

Agreements

On October 03, 2023, Sanofi, a global pharmaceutical company announced that it has entered into an agreement with Janssen Global Services, LLC, a global pharmaceutical company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli

Key Strategic Initiatives

In March 2021, Xiamen Innovax Biotech Co., Ltd, a China based biopharmaceutical company initiated a study Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) for the treatment of conditions such as Cervical Intraepithelial Neoplasia. The study is expected to be completed in January, 2024.

Figure 2. Global Escherichia Coli Strain Market Share (%), By Strain Type, 2023